Combating Hepatitis B and C to Reach Elimination by 2030 - Advocacy Brief. WHO. (2016)

immage

In 2013, viral hepatitis was a leading cause of death worldwide (1.46 million deaths, a toll higher than that from HIV, tuberculosis or malaria, and on the increase since 1990). More than 90% of this burden is due to the sequelae of infections with the hepatitis B virus (HBV) and hepatitis C virus (HCV).

Prevention can reduce the rate of new infections, but the number of those already infected would remain high for a generation. In the absence of additional efforts, 19 million hepatitis-related deaths are anticipated from 2015 to 2030. Treatment now can prevent deaths in the short- and medium term. 


Keywords: HIV, hepatitis B and C, treatment, prevention, testing


Download Publication

Policy Brief: WHO Recommends Assistance for People with HIV to Notify their Partners. WHO. (2016)

immage

The sexual partners and drug injecting partners of people diagnosed with HIV infection have an increased probability of also being HIV-positive.
Assisted HIV partner notification services are a simple and effective way to reach these partners, many of whom are undiagnosed and unaware of their HIV exposure, and may welcome support and an opportunity to test for HIV.
Assisted partner notification has been an important public health approach in infectious disease management for decades, including in programmes for sexually transmitted infections and tuberculosis, but has not been routinely implemented for people with HIV.


Keywords: HIV, partner, public health, testing, services

 

Download Publication

 

2016-17: A Percolating Pipeline. AVAC. (2016)

immage

While scaling up access to all treatment and prevention options that currently exist is essential, it is not sufficient. There remains a critical need for additional options. In addition to the introduction of oral-TDF based PrEP and the open-lable extension studies of the vaginal dapivirine ring, there are a number of efficacy trials planned or underway. They're tackling virtually every intervention—from next-generation PrEP in the form of F/TAF, a drug that will soon be tested for efficacy as daily oral PrEP, to long-acting injectables, vaccines and antibody-mediated prevention.


Keywords: HIV, PrEP,  antibody related, vaccine, microbicides

 

Download Infographic

Global Action Plan for HIV Drug Resistance 2016-2021. WHO. (2016)

immage

The World Health Organization (WHO) is committed to ensuring that the great success of HIV treatment scale-up is not threatened by HIV drug resistance (HIVDR). Preventing HIVDR is an important part of meeting the 90-90-90 targets by the year 2020.

The development of a five-year plan reflects a global consensus that HIVDR in lower and middle-income countries requires a coordinated and resourced response. The Global Action Plan is an agreement by key partners about their respective roles in preventing, monitoring, and responding to HIVDR.


Keywords: HIV, ART, treatment, prevention, drug-resistant

 

Download Publication

Trial Participants by Prevention Research Area, 2015. AVAC. (2016)

immage

Given the higher rates of acquisition seen across so-called key populations—members of highly burdened and underserved groups—it is critical to provide access to the research process such that they can participate and reap more immediate benefit of scientific progress. Greater efforts must be made to include key populations in this crucial process for the HIV prevention response to be truly impactful.

 

Excerpted from Px Wire.


Keywords:  HIV vaccine, microbicides, PrEP, treatment, male circumcision

 

Download Infographic

WHO Recommendations on Antenatal Care for a Positive Pregnancy Experience. WHO. (2016)

immage

Within the continuum of reproductive health care, antenatal care (ANC) provides a platform for important healthcare functions, including health promotion, screening and diagnosis, and disease prevention. It has been established that, by implementing timely and appropriate evidence-based practices, ANC can save lives.

 

Endorsed, by the UN Secretary-General, this is a comprehensive WHO guideline on routine ANC for pregnant women and adolescent girls. It aims to complement existing WHO guidelines on the management of specific pregnancy-related complications. The guidance aims to capture the complex nature of the issues surrounding ANC health care practices and delivery, and to prioritize person-centred health and well-being, not only the prevention of death and morbidity, in accordance with a human rights-based approach.

 

 

Keywords: ANC, women, pregnancy, children, adolescent

 

 

Download Publication and Executive Summary

Global Report on Early Warning Indicators of HIV Drug Resistance. WHO. (2016)

immage

With increasing global use of antiretroviral therapy (ART) to both treat and prevent HIV, and increasing global trends in HIV drug resistance ( HIVDR), efforts to improve HIV programme quality and prevent the emergence and transmission of drug-resistant HIV must be strengthened.

This global report is based on 59 countries that reported data from more than 12 000 clinics from cohorts of patients receiving ART between 2004 and 2014. The report includes the most recent clinic-level data reported to WHO in 2015 –2016 and reflects a lag due to the 12 month cohort reporting period.


Keywords: HIV infections, ART, drug resistance, viral, treatment

 

Download Publication

Cascade of HIV Testing, Care and Treatment Services, 2014 and 2015: Country profiles. WHO, Regional Office for South-East Asia. (2016)

immage

The publication presents cascade of HIV testing, care and treatment services, 2014–2015 for Bangladesh, Bhutan, India, Indonesia, Maldives, Myanmar, Nepal, Sri Lanka, Thailand and Timor Leste. 


Keywords: HIV, ANC, TB, PMTCT, testing, treatment, diagnosis 

 

 

Download Publication

Myanmar Case Study: Increasing Access to HIV Treatment. Mburu G, Paing AZ, Myint NN, Wang B, et al. (2016)

immage

There has been a rapid increase in the number of people living with HIV in Myanmar over the last decade, the majority of who are eligible for treatment. Alongside this increase has been an effort by the ministry of health to rapidly scale up provision of treatment in order to reduce HIV-related illnesses and deaths.

However, Myanmar has an ambitious national strategic goal of providing ART to 106,058 people by the end of 2016. The health system in Myanmar is already stretched, and to achieve this goal, innovation in ART delivery will be required in-order to ensure that ART is provided close to communities, without compromising quality.


Keywords: HIV, ART, healthcare, CD4 count, treatment

 

Download publication

 

Untangling the Web of Antiretroviral Price Reductions. Medecins Sans Frontieres (MSF). (2016)

immage

The report finds that prices of older HIV drugs continue to decline, while newer drugs remain largely priced out of reach. This is in large part because pharmaceutical corporations maintain monopolies that block price-lowering generic competition.

Today, the lowest available price for a quality-assured, World Health Organization-recommended first-line one-pill-a-day combination is US$100 per person per year (tenofovir/emtricitabine/efavirenz). This is a decrease of 26 per cent since MSF last recorded the lowest price for first-line treatment at US$136 in 2014. For a WHO-recommended second-line regimen, the lowest available price is now US$286 per person per year (zidovudine/lamivudine + atazanavir/ritonavir) – an 11 per cent decrease from US$322 two years ago.


Keywords: HIV, ARV, treatment, access, adults, children

 

Download Publication

Pages

database
Highlighted publications
http://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_HIV_drug_resistance_report_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Guidelines_on_public_health_response_to_pretreatment_HIV_drug_resistance_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Guidelines_for_Managing_Advanced_HIV_Disease_and_Rapid_Initiation_of_ART_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_What_New_in_Treatment_Monitoring_Viral_Load_and_CD4_Testing_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Pakistan_IBBS_2016-17.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Pakistan_Mapping_Key_Populations_2015-16.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_Global_AIDS_Update_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_Global_AIDS_Update_2017_Data_2017_en.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Myanmar_National_Strategic_Plan_on_HIV_and_AIDS_2016-2020.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_2017_Global_AIDS_Monitoring_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Nepal-IBBS-FIDU-Kathmandu-valley-RI-2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/NEC_HIV_May-AIDSreg2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_methods_for_deriving_estimates_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/2015_Size_Estimation_of_Key_Affected_Populations_in_Philippines.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Assessment_of_Decentralization_of_ART_in_MMR_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS-2016-prevention-gap-report_en.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_Biomedical_AIDS_research_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Implementing_comprehensive_HIV_and_STI_programmes_with_transgender_people_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_cities_ending_the_aids_epidemic_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Philippines_2015_IHBSS_Factsheets.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Integrating_collaborative_TB_and_HIV_services_within_a_comprehensive_package_of_care_for_PWID_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/India_IBBS_report_2014-15.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/India_HSS_report_2014-15.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/2015_young_people_drugs_en.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Transforming_our_world_2015_UN.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Consolidated_on_the_use_of_antiretroviral_drugs_for_treating_and_preventing_HIV_infection_2016.pdf
Calendar of events
Oct
11
Nov
14
Nov
20